Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428078 | 0.69 | GAK (0.42) | — | |
| SCHEMBL3399541 | 0.69 | NPC1 (0.47) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL610467 | 0.67 | NPC1 (0.36) | GAAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3424165 | 0.66 | MAOA (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3425514 | 0.62 | SIGMAR1 (0.47) | ALDH1A1HPGD | |
| SCHEMBL7152688 | 0.62 | — | — | |
| SCHEMBL4169913 | 0.61 | GAA (0.43) | GAAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9603304 | 0.61 | HPGD (0.33) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15882840 | 0.60 | EGFR (0.47) | ALDH1A1HPGD | |
| SCHEMBL8755108 | 0.60 | L3MBTL1 (0.41) | ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| EP-2603218-B1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| EP-2603218-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021580-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | GAA 3159/4885ALDH1A1 3151/4885HPGD 3069/4885 |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | GAA 3159/4885ALDH1A1 3151/4885HPGD 3069/4885 |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | GAA 3159/4885ALDH1A1 3151/4885HPGD 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.